CELEX: 62013CA0269
Language: en
Date: 2014-04-10 00:00:00
Title: Case C-269/13 P: Judgment of the Court (Sixth Chamber) of 10 April 2014  — Acino AG v European Commission (Appeal — Medicinal products for human use — Suspension of the marketing and the withdrawal of certain consignments of medicinal products containing the active ingredient Clopidogrel — Variation of marketing authorisations — Prohibition on marketing — Regulation (EC) No 726/2004 and Directive 2001/83/EC — Precautionary principle — Proportionality — Obligation to state reasons)

10.6.2014   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 175/14
            
         Judgment of the Court (Sixth Chamber) of 10 April 2014 — Acino AG v European Commission
   (Case C-269/13 P) (1)
   
   ((Appeal - Medicinal products for human use - Suspension of the marketing and the withdrawal of certain consignments of medicinal products containing the active ingredient Clopidogrel - Variation of marketing authorisations - Prohibition on marketing - Regulation (EC) No 726/2004 and Directive 2001/83/EC - Precautionary principle - Proportionality - Obligation to state reasons))
   2014/C 175/16
   Language of the case: German
   
      Parties
   
   
      Appellant: Acino AG (represented by: R. Buchner and E. Burk, Rechtsanwälte)
   
      Other party to the proceedings: European Commission (represented by: M. Šimerdová and B.-R. Killmann, acting as Agents)
   
      Re:
   
   Appeal against the judgment of the General Court (Seventh Chamber) of 7 March 2013 in Case T-539/10 Acino v Commission, in so far as that Court dismissed an application for annulment of Commission Decisions C (2010) 2203, C (2010) 2205, C (2010) 2210 and C (2010) 2218 of 29 March 2010 and Commission Decisions C (2010) 6430, C (2010) 6432, C (2010) 6434 and C (2010) 6435 of 16 September 2010, relating to the suspension of the marketing of medicinal products for human use containing the active ingredient Clopidogrel manufactured at a certain site, the withdrawal of consignments of those medicinal products from the market, the variation of the marketing authorisations and the prohibition on marketing those medicinal products — Precautionary principle — Proportionality — Obligation to state reasons
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the appeal.
            
         
               2.
            
            
               Orders Acino AG to pay the costs.
            
         
      (1)  OJ C 215, 27.07.2013.